TransCode Therapeutics Q1 EPS $(21.28) Up From $(70.16) YoY

Benzinga Newsdesk www.benzinga.com Negative 60.8%

Neg 60.8% Neu 0% Pos 0%

TransCode Therapeutics (NASDAQ:RNAZ) reported quarterly losses of $(21.28) per share. This is a 69.67 percent increase over losses of $(70.16) per share from the same period last year.